Skip to content

Effects of Leucine Supplementation in Patients with Stomach and Bowel Cancer.

Leucine supplementation in patients with gastrointestinal cancer: effects on body composition and inflammatory parameters

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
REBEC
Registry ID
RBR-7jv6k2n
Enrollment
Unknown
Registered
2025-10-16
Start date
2024-11-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Weight loss

Interventions

Double-blind, randomized, placebo-controlled study involving patients with gastrointestinal cancer, with or without cachexia. Volunteers will be randomly assigned to two groups: the Cancer with Cachex
and the Cancer Without Cachexia Group (CL n=30), who will receive 6g of leucine (CP n=15) or 6g of placebo (n=15). At the end of the study, there will be four groups: (CXL, CXP, CL, CP). These will be
G07.203.300.456

Sponsors

Faculdade de Medicina da Universidade de São Paulo
Lead Sponsor
Faculdade de Medicina da Universidade de São Paulo
Collaborator

Eligibility

Age
40 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients with gastrointestinal cancer (stomach, esophagus, colon, or rectum), with and without weight loss. Ages between 40 and 90 years. Both sexes

Exclusion criteria

Exclusion criteria: Neoplasms of organs adjacent to the gastrointestinal tract, such as the pancreas, liver, or small intestine. Autoimmune diseases, obesity, inflammatory bowel disease, Crohn's disease, acquired immunodeficiency syndrome, chronic obstructive pulmonary disease (COPD), and other inflammatory diseases were excluded. The presence of other types of cancer, kidney or liver failure, psychotic disorders, or dementia, as well as any cognitive condition that compromises the ability to respond to the questionnaires, was also considered an exclusion criterion. Individuals who used anti-inflammatory drugs or corticosteroids during the supplementation period were excluded from the study

Design outcomes

Primary

MeasureTime frame
Leucine supplementation is expected to modulate serum inflammatory cytokine expression using multiplex analysis and gut microbiota composition using 16S analysis. Additionally, patients' depression and anxiety scores will be assessed through questionnaires

Secondary

MeasureTime frame
Leucine supplementation is expected to modulate the expression of serum inflammatory cytokines and the composition of the intestinal microbiota

Countries

Brazil

Contacts

Public ContactMárcia Andrade

Universidade de São Paulo

marcia.andrade@usp.br+55(11)9462-29119

Outcome results

None listed

Source: REBEC (via WHO ICTRP)